Common concomitant medications across the four arms were antidiabetes drugs (such as glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), metformin, pioglitazone and sodium/glucose cotransporter-2 inhibitors) and drugs to manage dyslipidemia (statins, 46%). This evidence concerns the gene GLP1R and metabolic syndrome.